South Texas Money Management LTD Lifted Its Bristol (BMY) Stake; Amgen (AMGN) Has 1.22 Sentiment

May 23, 2018 - By Clifton Ray

Bristol-Myers Squibb Company (NYSE:BMY) Logo

South Texas Money Management Ltd increased Bristol (BMY) stake by 0.94% reported in 2017Q4 SEC filing. South Texas Money Management Ltd acquired 6,334 shares as Bristol (BMY)’s stock rose 2.38%. The South Texas Money Management Ltd holds 680,454 shares with $41.70M value, up from 674,120 last quarter. Bristol now has $85.50B valuation. The stock decreased 0.10% or $0.05 during the last trading session, reaching $52.29. About 2.69M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since May 23, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

Amgen Inc (AMGN) investors sentiment increased to 1.22 in 2017 Q4. It’s up 0.23, from 0.99 in 2017Q3. The ratio is positive, as 649 investment professionals increased or started new stock positions, while 531 sold and reduced their stock positions in Amgen Inc. The investment professionals in our database now possess: 551.71 million shares, down from 555.05 million shares in 2017Q3. Also, the number of investment professionals holding Amgen Inc in top ten stock positions decreased from 70 to 48 for a decrease of 22. Sold All: 73 Reduced: 458 Increased: 527 New Position: 122.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.09, from 1.03 in 2017Q3. It fall, as 72 investors sold BMY shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. Alyeska Inv Group Limited Partnership holds 0.31% or 590,334 shares. Nbt Bancorp N A New York has 1.05% invested in Bristol-Myers Squibb Company (NYSE:BMY). Partnervest Advisory Lc invested in 12,079 shares. Jennison Associates Limited holds 1.49% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 24.57M shares. Diligent Lc accumulated 0.61% or 15,555 shares. Axa invested 0.09% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). 1.80M were reported by State Of New Jersey Common Pension Fund D. Andra Ap owns 154,000 shares. Moreover, Planning Advisors Limited Liability has 0.76% invested in Bristol-Myers Squibb Company (NYSE:BMY). Brown Brothers Harriman & stated it has 90,962 shares or 0.03% of all its holdings. Texas Permanent School Fund accumulated 446,803 shares. Cypress Capital Ltd Liability Co (Wy) holds 0.09% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 1,350 shares. Moreover, Williams Jones Associate Ltd Com has 0.5% invested in Bristol-Myers Squibb Company (NYSE:BMY). Legal And General Gp Public Limited invested in 8.48M shares. Moreover, Gofen Glossberg Limited Il has 0.1% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 44,972 shares.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Bristol-Myers Squibb (BMY) Presents at UBS Global Healthcare Conference (Transcript)” on May 22, 2018, also Finance.Yahoo.com with their article: “Warren Buffett Loves TEVA Stock and You Should Too” published on May 23, 2018, Bizjournals.com published: “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer” on May 01, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Benzinga.com and their article: “BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position” published on April 27, 2018 as well as Fool.com‘s news article titled: “Why Bristol-Myers Squibb Stock Crashed in April” with publication date: May 09, 2018.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 2 Sell and 14 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 87 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was downgraded by Jefferies to “Hold” on Monday, October 16. Citigroup maintained it with “Buy” rating and $70 target in Tuesday, September 20 report. The firm earned “Underperform” rating on Friday, July 28 by BMO Capital Markets. SunTrust upgraded the shares of BMY in report on Monday, October 30 to “Buy” rating. The firm earned “Hold” rating on Friday, April 13 by Jefferies. The stock has “Hold” rating by Jefferies on Thursday, August 27. Piper Jaffray maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Friday, September 22. Piper Jaffray has “Hold” rating and $60.0 target. The firm has “Underweight” rating by Atlantic Securities given on Friday, December 18. Morgan Stanley downgraded the shares of BMY in report on Tuesday, April 17 to “Equal-Weight” rating. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Underperform” rating given on Wednesday, April 18 by BMO Capital Markets.

Since December 12, 2017, it had 2 insider buys, and 1 insider sale for $163,963 activity. $249,187 worth of Bristol-Myers Squibb Company (NYSE:BMY) shares were bought by Samuels Theodore R. II. Paliwal Dinesh C bought $249,948 worth of Bristol-Myers Squibb Company (NYSE:BMY) on Monday, April 30. The insider Lynch Thomas J. Jr. sold $335,172.

South Texas Money Management Ltd decreased Atos Se Unspon. Adr stake by 41,813 shares to 1.52 million valued at $44.18 million in 2017Q4. It also reduced Brown (NYSE:BF.B) stake by 435,495 shares and now owns 236,942 shares. Procter& Gamble Company (NYSE:PG) was reduced too.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company has market cap of $118.80 billion. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. It has a 66.31 P/E ratio. The companyÂ’s products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism ; and Erenumab for the prevention of migraine.

Since January 1, 0001, it had 0 insider buys, and 6 sales for $1.64 million activity.

Valueworks Llc holds 6.68% of its portfolio in Amgen Inc. for 51,635 shares. Tekla Capital Management Llc owns 862,174 shares or 5.78% of their US portfolio. Moreover, Merriman Wealth Management Llc has 5.7% invested in the company for 134,297 shares. The Washington-based Smead Capital Management Inc. has invested 5.4% in the stock. Krensavage Asset Management Llc, a New York-based fund reported 87,477 shares.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on July, 24. They expect $3.52 earnings per share, up 7.65% or $0.25 from last year’s $3.27 per share. AMGN’s profit will be $2.34B for 12.67 P/E if the $3.52 EPS becomes a reality. After $3.47 actual earnings per share reported by Amgen Inc. for the previous quarter, Wall Street now forecasts 1.44% EPS growth.

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: 247Wallst.com which released: “Amgen Wins Another FDA Approval” on May 22, 2018, also 247Wallst.com with their article: “Amgen’s Novel Migraine Treatment Gets Key Approval” published on May 18, 2018, Seekingalpha.com published: “Expanded label for Amgen’s Repatha approved in Europe” on May 16, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Seekingalpha.com and their article: “Amgen’s Dim Sales Outlook Looms Over Buybacks” published on April 26, 2018 as well as Streetinsider.com‘s news article titled: “Amgen (AMGN) Reports FDA Approval of Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis” with publication date: May 21, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>